Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81‐8973 from rFVIII‐FS can continue their dosing schedule with improved protection

Detalles Bibliográficos
Autores principales: Solms, Alexander, Lalezari, Shadan, Shah, Anita, Kenet, Gili
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383504/
https://www.ncbi.nlm.nih.gov/pubmed/32301248
http://dx.doi.org/10.1111/hae.13973
_version_ 1783563430581501952
author Solms, Alexander
Lalezari, Shadan
Shah, Anita
Kenet, Gili
author_facet Solms, Alexander
Lalezari, Shadan
Shah, Anita
Kenet, Gili
author_sort Solms, Alexander
collection PubMed
description
format Online
Article
Text
id pubmed-7383504
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-73835042020-07-27 Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81‐8973 from rFVIII‐FS can continue their dosing schedule with improved protection Solms, Alexander Lalezari, Shadan Shah, Anita Kenet, Gili Haemophilia Letters to the Editor John Wiley and Sons Inc. 2020-04-16 2020-05 /pmc/articles/PMC7383504/ /pubmed/32301248 http://dx.doi.org/10.1111/hae.13973 Text en © 2020 The Authors. Haemophilia published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Letters to the Editor
Solms, Alexander
Lalezari, Shadan
Shah, Anita
Kenet, Gili
Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81‐8973 from rFVIII‐FS can continue their dosing schedule with improved protection
title Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81‐8973 from rFVIII‐FS can continue their dosing schedule with improved protection
title_full Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81‐8973 from rFVIII‐FS can continue their dosing schedule with improved protection
title_fullStr Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81‐8973 from rFVIII‐FS can continue their dosing schedule with improved protection
title_full_unstemmed Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81‐8973 from rFVIII‐FS can continue their dosing schedule with improved protection
title_short Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81‐8973 from rFVIII‐FS can continue their dosing schedule with improved protection
title_sort population pharmacokinetic (poppk) modelling indicates that patients switching to bay 81‐8973 from rfviii‐fs can continue their dosing schedule with improved protection
topic Letters to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383504/
https://www.ncbi.nlm.nih.gov/pubmed/32301248
http://dx.doi.org/10.1111/hae.13973
work_keys_str_mv AT solmsalexander populationpharmacokineticpoppkmodellingindicatesthatpatientsswitchingtobay818973fromrfviiifscancontinuetheirdosingschedulewithimprovedprotection
AT lalezarishadan populationpharmacokineticpoppkmodellingindicatesthatpatientsswitchingtobay818973fromrfviiifscancontinuetheirdosingschedulewithimprovedprotection
AT shahanita populationpharmacokineticpoppkmodellingindicatesthatpatientsswitchingtobay818973fromrfviiifscancontinuetheirdosingschedulewithimprovedprotection
AT kenetgili populationpharmacokineticpoppkmodellingindicatesthatpatientsswitchingtobay818973fromrfviiifscancontinuetheirdosingschedulewithimprovedprotection

Ejemplares similares